In addition, when injected in a transgenic mouse model mimicking T2DM in humans, the mAb was able to reduce hyperglycemia, fibril formation in the islets, and decreased inflammation, while insulin-production remained largely normal. The gene discussed is INS; the disease is type 2 diabetes mellitus.